[1] Lin Y, Yang XJ. Application of tumor-treating fields method in the treatment of glioblastoma:from basic to clinical[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2019, 19:931-935.[林雨, 杨学军. 肿瘤治疗电场在胶质母细胞瘤治疗中的应用:从基础到临床[J]. 中国现代神经疾病杂志, 2019, 19:931-935.]
[2] Yang XJ. Practice what you learn, review what you've learned[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2019, 19:913-914.[杨学军. 勤学以致用温故而知新:与所有关心胶质瘤事业的同道共勉[J]. 中国现代神经疾病杂志, 2019, 19:913-914.]
[3] Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma:a randomized clinical trial[J]. JAMA, 2017, 318:2306-2316.
[4] Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma:a randomised phase Ⅲ trial of a novel treatment modality[J]. Eur J Cancer, 2012, 48:2192-2202.
[5] Shi W, Blumenthal DT, Oberheim Bush NA, Kebir S, Lukas RV, Muragaki Y, Zhu JJ, Glas M. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice[J]. J Neurooncol, 2020, 148:489-500.
[6] Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N. Clinical practice experience with NovoTTF-100ATM system for glioblastoma:the Patient Registry Dataset (PRiDe)[J]. Semin Oncol, 2014, 41 Suppl 6:4-13.
[7] Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma:a randomized clinical trial[J]. JAMA, 2015, 314:2535-2543. |